BACKGROUND: Conditional recurrence-free survival (RFS) probability, that is, the probability of remaining recurrence-free after a given interval without recurrence, has not been reported after resection of colorectal liver metastases (CLMs). We aimed to estimate conditional RFS and identify factors affecting conditional RFS. STUDY DESIGN: Patients undergoing initial resection of CLMs during 2000-2016 with mutation data were identified. The RFS and risk factors for recurrence were evaluated at the time of resection for all patients and at 1 year and 2 years after resection for patients who remained recurrence-free. RESULTS: Of 2,118 patients, 485 met the inclusion criteria, of which 225 were recurrence-free at 1 year and 109 were recurrence-free at 2 years. The 5-year RFS rates were 17.3%, 36.8%, and 70.7% for all patients and the 1-year and 2-year recurrence-free groups, respectively, when assessed from the time of initial CLM resection. RAS/TP53 co-mutation was the only factor independently associated with increased risk of recurrence for all groups (all patients, hazard ratio 1.47; 95% CI 1.19 to 1.82; p < 0.001; 1-year recurrence-free, hazard ratio 1.69; 95% CI 1.17 to 2.43; p = 0.005; 2-year recurrence-free, hazard ratio 2.41; 95% CI 1.12 to 5.17; p = 0.024). T category, extrahepatic disease, multiple CLMs, largest CLM diameter, and surgical margin status were risk factors for recurrence in all patients and/or the 1-year recurrence-free group, but not the 2-year recurrence-free group. Median RFS was lower for patients with RAS/TP53 co-mutation than for those with RAS/TP53 wild-type in the 1-year (1.5 vs 2.8 years; p = 0.006) and 2-year recurrence-free groups (3.0 vs 5.9 years; p = 0.024). CONCLUSIONS: Conditional RFS is useful for updating prognosis after a given time interval without recurrence after CLM resection. Importantly, RAS/TP53 co-mutation has a persistent deleterious association with recurrence.
BACKGROUND: Conditional recurrence-free survival (RFS) probability, that is, the probability of remaining recurrence-free after a given interval without recurrence, has not been reported after resection of colorectal liver metastases (CLMs). We aimed to estimate conditional RFS and identify factors affecting conditional RFS. STUDY DESIGN:Patients undergoing initial resection of CLMs during 2000-2016 with mutation data were identified. The RFS and risk factors for recurrence were evaluated at the time of resection for all patients and at 1 year and 2 years after resection for patients who remained recurrence-free. RESULTS: Of 2,118 patients, 485 met the inclusion criteria, of which 225 were recurrence-free at 1 year and 109 were recurrence-free at 2 years. The 5-year RFS rates were 17.3%, 36.8%, and 70.7% for all patients and the 1-year and 2-year recurrence-free groups, respectively, when assessed from the time of initial CLM resection. RAS/TP53 co-mutation was the only factor independently associated with increased risk of recurrence for all groups (all patients, hazard ratio 1.47; 95% CI 1.19 to 1.82; p < 0.001; 1-year recurrence-free, hazard ratio 1.69; 95% CI 1.17 to 2.43; p = 0.005; 2-year recurrence-free, hazard ratio 2.41; 95% CI 1.12 to 5.17; p = 0.024). T category, extrahepatic disease, multiple CLMs, largest CLM diameter, and surgical margin status were risk factors for recurrence in all patients and/or the 1-year recurrence-free group, but not the 2-year recurrence-free group. Median RFS was lower for patients with RAS/TP53 co-mutation than for those with RAS/TP53 wild-type in the 1-year (1.5 vs 2.8 years; p = 0.006) and 2-year recurrence-free groups (3.0 vs 5.9 years; p = 0.024). CONCLUSIONS: Conditional RFS is useful for updating prognosis after a given time interval without recurrence after CLM resection. Importantly, RAS/TP53 co-mutation has a persistent deleterious association with recurrence.
Authors: Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Antoine Brouquet; Eddie K Abdalla; Scott Kopetz; Christopher R Garrett; Michael J Overman; Cathy Eng; Andreas Andreou; Evelyne M Loyer; David C Madoff; Steven A Curley; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2011-01-24 Impact factor: 44.544
Authors: Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Jie Chen; Christoph Röcken; Cathy Lofton-Day; Hans-Ulrich Schulz; Oliver Müller; Nadine Kutzner; Peter Malfertheiner; Matthias P A Ebert Journal: Carcinogenesis Date: 2004-09-16 Impact factor: 4.944
Authors: Luca Viganò; Lorenzo Capussotti; Réal Lapointe; Eduardo Barroso; Catherine Hubert; Felice Giuliante; Jan N M Ijzermans; Darius F Mirza; Dominique Elias; René Adam Journal: Ann Surg Oncol Date: 2013-12-18 Impact factor: 5.344
Authors: Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2019-05 Impact factor: 12.969
Authors: Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley Journal: Ann Surg Date: 2004-06 Impact factor: 12.969
Authors: Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey Journal: Clin Cancer Res Date: 2019-06-20 Impact factor: 12.531
Authors: Yoshikuni Kawaguchi; Mario De Bellis; Elena Panettieri; Gregor Duwe; Jean-Nicolas Vauthey Journal: Surg Oncol Clin N Am Date: 2020-10-27 Impact factor: 3.495
Authors: Y Kawaguchi; S Kopetz; H S Tran Cao; E Panettieri; M De Bellis; Y Nishioka; H Hwang; X Wang; C-W D Tzeng; Y S Chun; T A Aloia; K Hasegawa; A Guglielmi; F Giuliante; J-N Vauthey Journal: Br J Surg Date: 2021-08-19 Impact factor: 6.939
Authors: Meredith C Mason; Ching-Wei D Tzeng; Hop S Tran Cao; Thomas A Aloia; Timothy E Newhook; Michael J Overman; Scott E Kopetz; Jean-Nicolas Vauthey; Yun Shin Chun Journal: J Am Coll Surg Date: 2021-03-02 Impact factor: 6.532
Authors: Yoshikuni Kawaguchi; Timothy E Newhook; Hop S Tran Cao; Ching-Wei D Tzeng; Yun Shin Chun; Thomas A Aloia; Arvind Dasari; Scott Kopetz; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2020-11-17 Impact factor: 3.452
Authors: Yoshikuni Kawaguchi; Scott Kopetz; Lawrence Kwong; Lianchun Xiao; Jeffrey S Morris; Hop S Tran Cao; Ching-Wei D Tzeng; Yun Shin Chun; Jeffrey E Lee; Jean-Nicolas Vauthey Journal: J Am Coll Surg Date: 2021-06-07 Impact factor: 6.532